AbbVie Acquires Celsius Therapeutics Acquires Celsius Therapeutics For $250M In Cash
Portfolio Pulse from Benzinga Newsdesk
AbbVie has acquired Celsius Therapeutics for $250 million in cash. Celsius' CEL383, a potential first-in-class anti-TREM1 antibody, is aimed at treating inflammatory bowel disease (IBD).
June 27, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has acquired Celsius Therapeutics for $250 million in cash, gaining access to CEL383, a potential first-in-class anti-TREM1 antibody for treating inflammatory bowel disease (IBD).
The acquisition of Celsius Therapeutics and its promising CEL383 antibody could strengthen AbbVie's portfolio in the treatment of inflammatory bowel disease, potentially driving future revenue growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100